CABOMETYX
Swiss trademark · 699534 · Combined mark · In force
Register entry
- Registration number
- 699534
- Application number
- 59180/2016
- Status
- In force
- Type
- Combined mark
- As registered
- CABOMETYX ((fig.))
- Filed
- Aug 2, 2016
- Registered
- Mar 6, 2017
- Published
- Mar 6, 2017
- Protected until
- Aug 2, 2036
- Priority
- 03.03.2016 US
- Language of procedure
- German
- Vienna classes
- 25.05.05, 26.03.04, 26.03.06, 26.03.24
- Source
- Swissreg
Goods and services
Pharmaceuticals
Pharmazeutische Präparate für die Behandlung von Krebs, Schmerzen, Infektionen, Entzündungen, hormonelle Störungen, Knochenstörungen und mentalen Störungen; Analgetika; Hormone für medizinische Zwecke; Psychopharmaka; Präparate gegen Infektionserreger; entzündungshemmende Mittel; Präparate zur Krebsbekämpfung.
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- Apr 13, 2026
Renewed
- Expiry date
- 02.08.2026 → 02.08.2036
Published in Swissreg on 13.04.2026
- Dec 14, 2023
Agent’s address changed
- Representative
- E. Blum & Co. AG, Patent- und Markenanwälte VSP, Vorderberg 11, 8044 Zürich → E. Blum & Co. AG, Hofwiesenstrasse 349, 8050 Zürich
Published in Swissreg on 14.12.2023
- Aug 14, 2019
Licensee entered
- Exclusive licensee
- Ipsen Pharma SAS, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France
Published in Swissreg on 14.08.2019
- Aug 13, 2019
Holder’s address changed
- Owner
- Exelixis, Inc., 210 East Grand Avenue, South San Francisco, CA 94080, USA → Exelixis, Inc., 1851 Harbor Bay Parkway, Alameda, CA 94502, USA
Published in Swissreg on 13.08.2019
- Mar 6, 2017
Registered
Published in Swissreg on 06.03.2017
Parties
Exclusive licensee
The register names each party by name and address. A party is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.